KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25.

Coline Montégut, Claire Falandry, Saverio Cinieri, Claire Cropet, Laure Montane, Frédérique Rousseau, Florence Joly, Malak Moubarak, Anna M Mosconi, Eva M Guerra-Alía, Christian Schauer, Hiroyuki Fujiwara, Ignace Vergote, Gabriella Parma, Gabriel Lindahl, Amélie Anota, Ulrich Canzler, Frederik Marmé, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Renaud Sabatier

Oncologist 30(7) oyae322

PMID39673779
PMCIDPMC12311279
DOI10.1093/oncolo/oyae322
发表日期2024-12-14
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:生活质量量表图;Figure 3:生活质量量表图。
摘要

摘要

BACKGROUND: In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life (QoL) of this combination in older patients in PAOLA-1. METHODS: Safety (CTCAE v4.03) and QoL (EORTC QoL Questionnaires Core 30 and Ovarian 28) data were collected. We compared safety by age (≥70 vs <70 years) in the olaparib-containing arm. QoL by treatment arm was assessed in older patients. Geriatric features, including Geriatric Vulnerability Score (GVS), were also gathered. RESULTS: Of 806 patients randomized, 142 were ≥70 years old (olaparib-containing arm: n = 104; placebo arm: n = 38). Older patients treated with olaparib exhibited a similar safety profile to younger patients, except for higher rates of all grades of lymphopenia and grade ≥3 hypertension (31.7% vs 21.6%, P =.032 and 26.9% vs 16.7%, P =.019, respectively). No hematological malignancy was reported. Two years after randomization, mean Global Health Status and cognitive functioning seemed better with olaparib than bevacizumab alone (adjusted mean difference: +4.47 points [95% CI, -0.49 to 9.42] and +4.82 [-0.57 to 10.21], respectively), and other QoL items were similar between arms. In the olaparib-containing arm, older patients with baseline GVS ≥ 1 (n = 48) exhibited increased toxicity and poorer QoL than those with GVS of 0 (n = 34). CONCLUSION: Among older patients in PAOLA-1, olaparib plus bevacizumab had a manageable safety profile and no adverse impact on QoL. Additional data are required to confirm these results in more vulnerable patients.(ClinicalTrials.gov Identifier: NCT02477644).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Study flow diagram. GVS, Geriatric Vulnerability Score; QoL, quality of life.
非 KM Figure
Figure 2Figure 2. Least-squares mean change from baseline to month 24 of the functional (A) and symptomatic domain (B) EORTC QLQ-C30 scores and the functional (C) and symptomatic domain (D) EORTC QLQ-OV28 scores in older patients (≥70 years old). *Clinically significant difference, according to Musoro et al. CT, chemotherapy; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; EORTC QLQ-OV28, European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Ovarian 28; GHS, Global Health Status; GI, gastrointestinal; LS, least-squares; QoL, quality of life.
非 KM Figure
Figure 3Figure 3. Least-squares mean longitudinal change from baseline to month 24 of selected EORTC QLQ-C30 scores in older patients (≥70 years old) receiving olaparib according to GVS group. Results from fatigue and nausea and vomiting scores have been reversed on the graph so that a positive change will correspond with an improvement. *Clinically significant difference, according to Musoro et al. EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; GVS, Geriatric Vulnerability Score; LS, least-squares.
非 KM Figure